Endometriosis affects 190 million women and girls. Our team is developing better diagnostics and treatments for this understudied gynecologic disorder.
Endometriosis is characterized by the abnormal growth of tissue resembling the endometrium outside the uterus. It is estimated to affect 10–15% of reproductive-aged women and is associated with significant morbidity, including chronic pelvic pain and infertility. With no curative treatments currently available, standard therapies rely on hormonal suppression or invasive surgery, both of which are associated with substantial side effects and high rates of disease recurrence.
ENDOx integrates expertise in nanoparticle engineering, molecular profiling, human-relevant in vitro systems, lesion biology informed by animal models, and product development in women’s health to address these limitations. Together with Boston-based clinical experts, we are evaluating disease-targeting nanoparticles in human-relevant experimental systems, enabling mechanism-guided assessment of therapeutic response and establishing a translational foundation applicable to other gynecologic diseases.
The convergence of targeted nanoparticle technologies, human-relevant models that more accurately recapitulate lesion microenvironments, and modern proteomic tools capable of providing mechanistic insight, creates a unique opportunity to move beyond symptom management toward disease-targeted treatment.